Based on 8 analysts giving stock ratings to Entrada Therapeutics Inc in the past month.
In the current month, TRDA has received 4 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. TRDA average Analyst price target in the last month is 16.648.
Based on analysts' estimates, TRDA EPS is projected to reach -1.020 in FY2026Q4, following reported EPS of -0.938 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.94, while Entrada Therapeutics IncTRDA's earnings per share (EPS) for the previous quarter was USD -1.01. EPS for the next quarter is expected at USD -1.02.